BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 16955531)

  • 41. Melatonin receptor agonist ramelteon activates the extracellular signal-regulated kinase 1/2 in mouse cerebellar granule cells.
    Imbesi M; Uz T; Manev H
    Neuroscience; 2008 Sep; 155(4):1160-4. PubMed ID: 18664376
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives.
    Landagaray E; Ettaoussi M; Leclerc V; Traoré B; Perez V; Nosjean O; Boutin JA; Caignard DH; Delagrange P; Berthelot P; Yous S
    Bioorg Med Chem; 2014 Feb; 22(3):986-96. PubMed ID: 24417958
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A new melatonin receptor ligand with mt1-agonist and MT2-antagonist properties.
    Nonno R; Lucini V; Spadoni G; Pannacci M; Croce A; Esposti D; Balsamini C; Tarzia G; Fraschini F; Stankov BM
    J Pineal Res; 2000 Nov; 29(4):234-40. PubMed ID: 11068946
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New selective ligands of human cloned melatonin MT1 and MT2 receptors.
    Audinot V; Mailliet F; Lahaye-Brasseur C; Bonnaud A; Le Gall A; Amossé C; Dromaint S; Rodriguez M; Nagel N; Galizzi JP; Malpaux B; Guillaumet G; Lesieur D; Lefoulon F; Renard P; Delagrange P; Boutin JA
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Jun; 367(6):553-61. PubMed ID: 12764576
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Melatonin reverses the expression of morphine-induced conditioned place preference through its receptors within central nervous system in mice.
    Han J; Xu Y; Yu CX; Shen J; Wei YM
    Eur J Pharmacol; 2008 Oct; 594(1-3):125-31. PubMed ID: 18706407
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficient synthesis of hexahydroindenopyridines and their potential as melatoninergic ligands.
    Párraga J; Moreno L; Diaz A; El Aouad N; Galán A; Sanz MJ; Caignard DH; Figadère B; Cabedo N; Cortes D
    Eur J Med Chem; 2014 Oct; 86():700-9. PubMed ID: 25232966
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.
    Koike T; Takai T; Hoashi Y; Nakayama M; Kosugi Y; Nakashima M; Yoshikubo S; Hirai K; Uchikawa O
    J Med Chem; 2011 Jun; 54(12):4207-18. PubMed ID: 21568291
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.
    Landagaray E; Ettaoussi M; Duroux R; Boutin JA; Caignard DH; Delagrange P; Melnyk P; Berthelot P; Yous S
    Eur J Med Chem; 2016 Feb; 109():360-70. PubMed ID: 26820449
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives.
    Bedini A; Lucarini S; Spadoni G; Tarzia G; Scaglione F; Dugnani S; Pannacci M; Lucini V; Carmi C; Pala D; Rivara S; Mor M
    J Med Chem; 2011 Dec; 54(24):8362-72. PubMed ID: 22047556
    [TBL] [Abstract][Full Text] [Related]  

  • 50. N-[2-[2-(4-Phenylbutyl)benzofuran-4-yl]cyclopropylmethyl]acetamide: an orally bioavailable melatonin receptor agonist.
    Sun LQ; Takaki K; Chen J; Iben L; Knipe JO; Pajor L; Mahle CD; Ryan E; Xu C
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5157-60. PubMed ID: 15380218
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular modeling of human MT2 melatonin receptor: the role of Val204, Leu272 and Tyr298 in ligand binding.
    Mazna P; Obsilova V; Jelinkova I; Balik A; Berka K; Sovova Z; Ettrich R; Svoboda P; Obsil T; Teisinger J
    J Neurochem; 2004 Nov; 91(4):836-42. PubMed ID: 15525337
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits.
    Alarma-Estrany P; Guzman-Aranguez A; Huete F; Peral A; Plourde R; Pelaez T; Yerxa B; Pintor J
    J Pharmacol Exp Ther; 2011 Jun; 337(3):703-9. PubMed ID: 21368006
    [TBL] [Abstract][Full Text] [Related]  

  • 53. (R)-2-(4-Phenylbutyl)dihydrobenzofuran derivatives as melatoninergic agents.
    Sun LQ; Takaki K; Chen J; Bertenshaw S; Iben L; Mahle CD; Ryan E; Wu D; Gao Q; Xu C
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1345-9. PubMed ID: 15713384
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3.
    Ettaoussi M; Péres B; Klupsch F; Delagrange P; Boutin JA; Renard P; Caignard DH; Chavatte P; Berthelot P; Lesieur D; Yous S
    Bioorg Med Chem; 2008 May; 16(9):4954-62. PubMed ID: 18372181
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis and functional characterization of substituted isoquinolinones as MT2-selective melatoninergic ligands.
    Hu Y; Chan KH; He X; Ho MK; Wong YH
    PLoS One; 2014; 9(12):e113638. PubMed ID: 25479338
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.
    Leclerc V; Ettaoussi M; Rami M; Farce A; Boutin JA; Delagrange P; Caignard DH; Renard P; Berthelot P; Yous S
    Eur J Med Chem; 2011 May; 46(5):1622-9. PubMed ID: 21377769
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic potential of melatonin ligands.
    Delagrange P; Boutin JA
    Chronobiol Int; 2006; 23(1-2):413-8. PubMed ID: 16687314
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reassessing the melatonin pharmacophore--enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue.
    Rivara S; Diamantini G; Di Giacomo B; Lamba D; Gatti G; Lucini V; Pannacci M; Mor M; Spadoni G; Tarzia G
    Bioorg Med Chem; 2006 May; 14(10):3383-91. PubMed ID: 16431121
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides.
    Rivara S; Pala D; Lodola A; Mor M; Lucini V; Dugnani S; Scaglione F; Bedini A; Lucarini S; Tarzia G; Spadoni G
    ChemMedChem; 2012 Nov; 7(11):1954-64. PubMed ID: 22927210
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The expression of MT1 and MT2 melatonin receptor mRNA in several rat tissues.
    Sallinen P; Saarela S; Ilves M; Vakkuri O; Leppäluoto J
    Life Sci; 2005 Jan; 76(10):1123-34. PubMed ID: 15620576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.